Almonertinib With Chemotherapy in mEGFR NSCLC

Summary

The reason for the study is to find out if an experimental combination of an oral medication called Almonertinib when used in combination with chemotherapy is more effective for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR).

Timeline

Start

2020-11-19

Primary completion

2020-11-28

Completion

2022-11-25

Publications

• Li Y, Li C, Zhao X, Li Y, He F, Pan Z. Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. Oncologist. 2025 Mar 10;30(3):oyae336. doi: 10.1093/oncolo/oyae336.

Drugs

Indications